Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

1. Targeted Therapies in Cancer: To Be or Not to Be, Selective.Biomedicines · 2021
   Review
2. Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.Oncotarget · 2018
   Article
3. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.PloS one · 2014
   Article
4. Dabrafenib and its potential for the treatment of metastatic melanoma.Drug design, development and therapy · 2012
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as